Prosecution Insights
Last updated: May 29, 2026

Examiner: YU, DAVID TUYANG

Tech Center 1600 • Art Units: 1600 1633 1635 1657

This examiner grants 0% of resolved cases

Performance Statistics

Allow Rate
-60.0% vs TC avg
20
Total Applications
Interview Lift
0
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

0%
§101 Eligibility
4.2%
§102 Novelty
45.8%
§103 Obviousness
12.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17937614 THERMAL STATE SWITCHES IN MACROPHAGES Non-Final OA California Institute of Technology
18357495 RNAI CONSTRUCTS AND METHODS FOR INHIBITING FAM13A EXPRESSION Non-Final OA AMGEN INC.
18254893 COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ANGELMAN SYNDROME Non-Final OA The Trustees of the University of Pennsylvania
18375206 OCULAR DELIVERY OF OLIGONUCLEOTIDES Non-Final OA UNIVERSITY OF MASSACHUSETTS
17917953 ANTISENSE SEQUENCES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS Non-Final OA SORBONNE UNIVERSITE
18031547 COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A Non-Final OA Beam Therapeutics Inc.
18280779 Methods for Delivering a Cargo Into a Cell Non-Final OA TRINCE BV
18455035 TECHNOLOGY PLATFORM OF UNCAPPED-LINEAR MRNA WITH UNMODIFIED URIDINE Non-Final OA Binhui Biopharmaceutical Co., Ltd
18363976 ENGINEERED LEUCINE DECARBOXYLASES Non-Final OA Syntis Bio , Inc.
18254086 CRISPR RIBONUCLEOPROTEIN COMPLEX GENOME EDITING OF HUMAN INNATE IMMUNE CELLS Non-Final OA The Regents if the University of California

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month